Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Sees Large Decline in Short Interest

Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) was the target of a significant decline in short interest in February. As of February 13th, there was short interest totaling 1,533 shares, a decline of 53.3% from the January 29th total of 3,281 shares. Based on an average daily volume of 5,511 shares, the days-to-cover ratio is currently 0.3 days. Approximately 0.0% of the shares of the company are short sold. Approximately 0.0% of the shares of the company are short sold. Based on an average daily volume of 5,511 shares, the days-to-cover ratio is currently 0.3 days.

Invesco Biotechnology & Genome ETF Stock Up 0.8%

Invesco Biotechnology & Genome ETF stock traded up $0.63 during trading hours on Friday, hitting $81.97. 269 shares of the company traded hands, compared to its average volume of 6,576. Invesco Biotechnology & Genome ETF has a 1-year low of $54.52 and a 1-year high of $85.73. The firm has a market cap of $263.12 million, a P/E ratio of 20.44 and a beta of 0.79. The firm’s 50-day simple moving average is $82.59 and its two-hundred day simple moving average is $76.76.

Institutional Trading of Invesco Biotechnology & Genome ETF

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Invesco Biotechnology & Genome ETF by 9,169.5% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 342,971 shares of the company’s stock valued at $28,175,000 after buying an additional 339,271 shares during the period. United Capital Financial Advisors LLC acquired a new stake in Invesco Biotechnology & Genome ETF in the 3rd quarter valued at about $5,946,000. Q3 Asset Management bought a new position in shares of Invesco Biotechnology & Genome ETF during the 4th quarter valued at about $1,431,000. Royal Bank of Canada grew its stake in shares of Invesco Biotechnology & Genome ETF by 22.3% in the 1st quarter. Royal Bank of Canada now owns 75,402 shares of the company’s stock worth $4,783,000 after purchasing an additional 13,767 shares during the last quarter. Finally, Gerber Kawasaki Wealth & Investment Management grew its stake in shares of Invesco Biotechnology & Genome ETF by 4.2% in the 2nd quarter. Gerber Kawasaki Wealth & Investment Management now owns 254,172 shares of the company’s stock worth $16,292,000 after purchasing an additional 10,213 shares during the last quarter.

About Invesco Biotechnology & Genome ETF

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.